SCHEMBL5728014

SCHEMBL5728014

O=C1CSC(=S)N1Cc1ccco1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 4/20 0.59
GSK3B P49841 4/20 0.59
MEN1 O00255 7/20 0.55
KMT2A Q03164 7/20 0.55
MAPT P10636 7/20 0.55
POLB P06746 5/20 0.55
TDP1 Q9NUW8 5/20 0.55
RECQL P46063 4/20 0.55
THRB P10828 3/20 0.55
USP2 O75604 2/20 0.55
HPGD P15428 2/20 0.55
ALOX12 P18054 2/20 0.55
APEX1 P27695 2/20 0.55
KDM4E B2RXH2 1/20 0.55
BLM P54132 1/20 0.55
ALDH1A1 P00352 8/20 0.54
RAB9A P51151 2/20 0.54
HSD17B10 Q99714 4/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23009248 0.75 KDM4E (0.63) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL11157478 0.75 MAPT (0.61) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL6734762 0.74 GSK3A (0.60) GSK3AGSK3BMEN1KMT2AMAPT
SCHEMBL9069344 0.73 GSK3A (0.63) GSK3AGSK3BMEN1KMT2AMAPT
SCHEMBL31411564 0.71 POLB (0.47) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL31411521 0.71 POLB (0.59) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL31411587 0.71 MAPT (0.67) KMT2AMAPTPOLBTDP1HPGD
SCHEMBL17263340 0.71 ALDH1A1 (0.53) MEN1KMT2AMAPTPOLBTDP1
SCHEMBL20339802 0.70 GSK3B (0.63) GSK3AGSK3BMEN1KMT2AMAPT
SCHEMBL20339669 0.70 GSK3A (0.68) GSK3AGSK3BMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649231-B2 Compound as mTOR inhibitor and use thereof MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2023-05-16 US disclosed
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) 2021-09-23 US disclosed
EP-3786163-A1 NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF Medicinal Bioconvergence Research Center (KR) 2021-03-03 EP disclosed
CN-112368279-A Novel compounds as mTOR inhibitors and uses thereof 医药生命融合研究团 2021-02-12 CN disclosed
EP-1653954-A1 ANTIBIOTIC THIAZOLIDINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-05-10 EP disclosed
WO-2005020990-A1 ANTIBIOTIC THIAZOLIDINES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2005-03-10 WO disclosed
EP-0861843-B1 Fluorescent ionophoric compounds with a cryptand/crown-ether portion and a coumarin portion, their preparation and their use for measuring metal cation concentrations TERUMO CARDIOVASCULAR SYS (US) 2004-07-14 EP disclosed
EP-1204671-B1 FLUOROGENIC COMPOUNDS AND USES THEREFOR 3M INNOVATIVE PROPERTIES CO (US) 2003-12-03 EP disclosed
US-6566508-B2 Compound for use in the accurate detection of food parasites 3M INNOVATIVE PROPERTIES COMPANY 2003-05-20 US disclosed
US-20020147317-A1 Fluorogenic compounds and uses therefor 3M INNOVATIVE PROPETIES COMPANY 2002-10-10 US disclosed
US-6372895-B1 USEFUL IN ASSAYING FOR BIOLOGICAL ACTIVITY 3M INNOVATIVE PROPERTIES COMPANY 2002-04-16 US disclosed
WO-2001010881-A1 FLUOROGENIC COMPOUNDS AND USES THEREFOR 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-02-15 WO disclosed
WO-2000032598-A9 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC (US) 2000-11-30 WO disclosed
WO-2000032598-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC. (US) 2000-06-08 WO disclosed
US-5958782-A FLUORESCENT IONOPHORIC COMPOUND IS DISCLOSED THAT INCLUDES A COMPLEXING MOIETY, SUCH AS A CRYPTAND OR CROWN-ETHER PORTION, AND A FLUORESCING MOIETY SUCH AS A COUMARIN PORTION MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-09-28 US disclosed
EP-0861843-A2 Fluorescent ionophoric compounds with a cryptand/crown-ether portion and a coumarin portion, their preparation and their use for measuring metal cation concentrations MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-09-02 EP disclosed
US-5587279-A HIGH CONCENTRATION OF SILVER CHLORIDE GRAINS FUJI PHOTO FILM CO., LTD. (JP) 1996-12-24 US disclosed
EP-0185100-B1 PROCESS FOR PREPARING SILVER HALIDE EMULSION FUJI PHOTO FILM CO LTD (JP) 1990-05-30 EP disclosed
US-4713321-A SENSITIZING DYES, OXIDIZERS SUCH AS PEROXIDES FUJI PHOTO FILM CO., LTD. (JP) 1987-12-15 US disclosed
EP-0185100-A1 PROCESS FOR PREPARING SILVER HALIDE EMULSION FUJI PHOTO FILM CO., LTD. (JP) 1986-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649231-B2 Compound as mTOR inhibitor and use thereof MTOR, RICTOR, RPTOR GSK3A 103/4885GSK3B 75/4885MEN1 855/4885
US-20020147317-A1 Fluorogenic compounds and uses therefor NOTUM, WEE1, CPSF7 GSK3A 2010/4885GSK3B 1872/4885MEN1 852/4885
US-20210292314-A1 NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF MTOR, RICTOR, RPTOR GSK3A 143/4885GSK3B 110/4885MEN1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.